The FDA's 2027 budget proposal includes a $200 million increase focused on strengthening regulatory frameworks and accelerating drug development1
The proposal aims to make rare disease vouchers a permanent program, signaling long-term commitment to supporting innovation in the rare disease space1
The budget includes initiatives to facilitate easier clinical trial entry, reducing time and administrative burden for drug developers1
As of late 2025, the FDA had awarded more than 60 rare pediatric disease priority review vouchers covering dozens of rare pediatric diseases2
Priority review vouchers shorten FDA's standard 10-month review timeline to approximately 6 months, and have sold for more than $100 million in private transactions2
Congress extended the Rare Pediatric Disease Priority Review Voucher program through September 30, 2029, via the Consolidated Appropriations Act, 202623
The FDA's total proposed FY 2027 budget is $7.2 billion, representing a 3.3 percent increase above the FY 2026 enacted level4
In 2025, 18 products received priority review vouchers under the program4
The budget proposal also includes enhancements for national security, medical supply chain safeguarding, and promotion of 'radical transparency' in regulatory activities1
Sources:
1. https://www.thebiointel.com/article/fda-2027-budget-permanent-rare-disease-vouchers-easier-entry-clinic
2. https://www.spencerfane.com/insight/congress-extends-rare-pediatric-disease-priority-review-voucher-program-through-2029/
3. https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/rare-pediatric-disease-designation-and-priority-review-voucher-programs